NorthWest Biotherapeutics Inc (NWBO)

[Roman516]

With respect to your post "KPS over 80, not over 90 is a prognostic indicator for survival. The slight difference of 5% more over 90 in the ECA nGBM group can’t begin to explain the consistent statistically significant difference in the survival curve.

Most strikingly, the differences in very long term survival cannot be explained by the slight differences. In both nGBM and rGBM, the survival gap increases substantially over time. For gosh sake Jerry, the ECAs had a pool of 1366 patients to begin with, and none were proven to be alive (beating heartbeats) at five years. They relied exclusively on censoring lost to follow up and gimmicks to achieve 5.7% five year survival.

Whereas, in comparison, DCVax-l started with only 232 patients, and still had 25 at risk (beating heartbeats) and even without using censorship had nearly 11% alive and with censorship 13% alive at five years. I really can’t help you Jerry if you don’t get this. Where are the beating heartbeats in the ECA at five years Jerry? Where are they?" Great response with the facts and date numbers. Wow, if the trial for DCVax-L had 1266 patients instead of 232, DCVax-L results would even be more impressive with respect to the long-term survival period of 5-years. Either way, the math, the science, and the statistics are all positive indicators for DCVax-L to continue to move forward. You would think that the RA's would move forward with DCVax-L soon, weeks not months. The more delays, the more cancer patients will continue to die.